Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Cushing’s Syndrome and Cardiovascular Risk

Author(s): Panagiotis Anagnostis* and Dimitrios G. Goulis

Volume 18, Issue 1, 2020

Page: [25 - 26] Pages: 2

DOI: 10.2174/1570161117999190318142847

« Previous Next »
[1]
Koracevic G, Stojkovic M, Lovic D, et al. Should Cushing’s syndrome be considered as a disease with high cardiovascular risk in relevant guidelines? Curr Vasc Pharmacol 2020; 18: 12-24.
[2]
Loriaux DL. Diagnosis and differential diagnosis of cushing’s syndrome. N Engl J Med 2017; 376: 1451-9.
[3]
Chiodini I, Albani A, Ambrogio AG, et al. Six controversial issues on subclinical Cushing’s syndrome. Endocrine 2017; 56: 262-6.
[4]
Anagnostis P, Karagiannis A, Tziomalos K, Kakafika AI, Athyros VG, Mikhailidis DP. Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) 2009; 8: 163-84.
[5]
Anagnostis P, Efstathiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas--a single center experience and review of the literature. Exp Clin Endocrinol Diabetes 2010; 118: 610-6.
[6]
Hizume T, Morikawa K, Takaki A, et al. Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: A possible link between stress and coronary vasospasm. Circ Res 2006; 99: 767-75.
[7]
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 2009; 94: 2692-701.
[8]
Anagnostis P, Katsiki N, Adamidou F, et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: Novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 2013; 62: 21-33.
[9]
Clayton RN, Jones PW, Reulen RC, et al. Mortality in patients with Cushing’s disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4: 569-76.
[10]
Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing’s syndrome: Systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169: 715-23.
[11]
Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: Audit and meta-analysis of literature. J Clin Endocrinol Metab 2011; 96: 632-42.
[12]
Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jorgensen JO. Mortality in Cushing’s syndrome: A systematic review and meta-analysis. Eur J Intern Med 2012; 23: 278-82.
[13]
Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: A 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2: 396-405.
[14]
Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: A 13-year retrospective study from one center. Endocrine 2017; 58: 267-75.
[15]
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 2014; 99: 4462-70.
[16]
Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocr Rev 2015; 36: 385-486.
[17]
Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: A prospective randomized study. Ann Surg 2009; 249: 388-91.
[18]
Bancos I, Alahdab F, Crowley RK, et al. Therapy of endocrine disease: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing’s syndrome: A systematic review and meta-analysis. Eur J Endocrinol 2016; 175: 283-95.
[19]
Terzolo M, Pia A, Reimondo G. Subclinical Cushing’s syndrome: Definition and management. Clin Endocrinol (Oxf) 2012; 76: 12-8.
[20]
Anagnostis P, Karras SN, Athyros VG, Mikhailidis DP, Karagiannis A. Subclinical Cushing’s syndrome and cardiovascular disease. Lancet Diabetes Endocrinol 2014; 2: 361.

Rights & Permissions Print Cite
Article Metrics
35
2
© 2024 Bentham Science Publishers | Privacy Policy